$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

$auph Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000162828022013439 Filed on May 10, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$21.63M	$914.0K
YoY Change	2265.97%	2946.67%
Cost Of Revenue	$256.0K	$48.00K
YoY Change	433.33%
Gross Profit	$21.37M	$866.0K
YoY Change	2367.55%	2786.67%
Gross Profit Margin	98.82%	94.75%
Selling, General & Admin	$45.20M	$39.28M
YoY Change	15.06%	255.49%
% of Gross Profit	211.51%	4536.03%
Research & Development	$12.62M	$9.833M
YoY Change	28.34%	-28.93%
% of Gross Profit	59.06%	1135.45%
Depreciation & Amortization	$687.0K	$688.0K
YoY Change	-0.15%
% of Gross Profit	3.21%	79.45%
Operating Expenses	$12.62M	$51.46M
YoY Change	-75.47%	89.95%
Operating Profit	-$37.88M	-$50.54M
YoY Change	-25.05%	86.78%
Interest Expense	$262.0K	$172.0K
YoY Change	52.33%	-80.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$37.62M	-$50.37M
YoY Change	-25.31%	92.48%
Income Tax	$10.00K	$8.000K
% Of Pretax Income
Net Earnings	-$37.63M	-$50.38M
YoY Change	-25.31%	94.27%
Net Earnings / Revenue	-174.01%	-5511.93%
Basic Earnings Per Share	-$0.27	-$0.40
Diluted Earnings Per Share	-$0.27	-$0.40
COMMON SHARES
Basic Shares Outstanding	141.7M shares	127.4M shares
Diluted Shares Outstanding	141.7M shares	127.4M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$418.8M	$348.3M
YoY Change	20.24%	21.73%
Cash & Equivalents	$131.6M	$156.6M
Short-Term Investments	$286.2M	$191.7M
Other Short-Term Assets	$3.966M	$1.180M
YoY Change	236.1%	-85.78%
Inventory	$26.27M	$15.94M
Prepaid Expenses	$12.20M	$6.864M
Receivables	$20.40M	$1.187M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$477.6M	$372.2M
YoY Change	28.31%	24.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.332M	$4.758M
YoY Change	-8.95%	-19.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$12.60M
YoY Change
Other Assets	$11.84M	$11.86M
YoY Change	-0.15%	5828.0%
Total Long-Term Assets	$29.28M	$44.83M
YoY Change	-34.68%	202.92%
TOTAL ASSETS
Total Short-Term Assets	$477.6M	$372.2M
Total Long-Term Assets	$29.28M	$44.83M
Total Assets	$506.9M	$417.1M
YoY Change	21.54%	33.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.267M	$2.182M
YoY Change	49.73%	-82.4%
Accrued Expenses	$30.07M	$16.59M
YoY Change	81.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$33.84M	$21.15M
YoY Change	59.98%	45.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$17.40M	$17.90M
YoY Change	-2.79%	-6.28%
Total Long-Term Liabilities	$17.40M	$17.90M
YoY Change	-2.79%	-6.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.84M	$21.15M
Total Long-Term Liabilities	$17.40M	$17.90M
Total Liabilities	$58.78M	$46.85M
YoY Change	25.46%	39.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$793.8M	-$625.5M
YoY Change	26.89%
Common Stock	$64.69M	$43.89M
YoY Change	47.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$448.1M	$370.2M
YoY Change
Total Liabilities & Shareholders Equity	$506.9M	$417.1M
YoY Change	21.54%	33.38%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$37.63M	-$50.38M
YoY Change	-25.31%	94.27%
Depreciation, Depletion And Amortization	$687.0K	$688.0K
YoY Change	-0.15%
Cash From Operating Activities	-$46.75M	-$53.54M
YoY Change	-12.69%	136.82%
INVESTING ACTIVITIES
Capital Expenditures	-$79.00K	-$1.181M
YoY Change	-93.31%	-662.38%
Acquisitions
YoY Change
Other Investing Activities	-$52.94M	-$66.07M
YoY Change	-19.87%	454.71%
Cash From Investing Activities	-$53.02M	-$67.25M
YoY Change	-21.16%	454.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$405.0K	$5.029M
YoY Change	-91.95%	72.11%
NET CHANGE
Cash From Operating Activities	-$46.75M	-$53.54M
Cash From Investing Activities	-$53.02M	-$67.25M
Cash From Financing Activities	$405.0K	$5.029M
Net Change In Cash	-$99.36M	-$115.8M
YoY Change	-14.17%	263.88%
FREE CASH FLOW
Cash From Operating Activities	-$46.75M	-$53.54M
Capital Expenditures	-$79.00K	-$1.181M
Free Cash Flow	-$46.67M	-$52.36M
YoY Change	-10.87%	129.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001600620
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	City Area Code CityAreaCode	(250)
CY2022Q1	dei	Entity File Number EntityFileNumber	001-36421
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Aurinia Pharmaceuticals Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Z4
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	#1203-4464 Markham Street
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Victoria
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V8Z 7X8
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1231763
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	708-4272
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	141741580	shares
CY2022Q1	dei	Security12b Title Security12bTitle	Common shares, no par value
CY2022Q1	dei	Trading Symbol TradingSymbol	AUPH
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132542000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231900000	USD
CY2022Q1	us-gaap	Debt Securities Current DebtSecuritiesCurrent	286210000	USD
CY2021Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	234178000	USD
CY2022Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	20401000	USD
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15414000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	26266000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	19326000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12199000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12506000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	477618000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	513324000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11838000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11838000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4332000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4418000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7882000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8404000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5232000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5383000	USD
CY2022Q1	us-gaap	Assets Assets	506902000	USD
CY2021Q4	us-gaap	Assets Assets	543367000	USD
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	32327000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	34947000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	502000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4640000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1009000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1059000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	33838000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40646000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	17379000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15950000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7562000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7680000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	58779000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	64276000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141742000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141742000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141600000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141600000	shares
CY2022Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1178807000	USD
CY2021Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1177051000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	64686000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	59014000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1618000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-852000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-793752000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-756122000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	448123000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	479091000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	506902000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	543367000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21625000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	914000	USD
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	256000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	48000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45197000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39805000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12620000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9833000	USD
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1434000	USD
CY2021Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1771000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	59507000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	51457000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-37882000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-50543000	USD
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	262000	USD
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	172000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37620000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-50371000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-37630000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-50379000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-766000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38396000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50373000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141675000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141675000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127401000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	127401000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	479091000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	405000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7023000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-766000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-37630000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	448123000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	407750000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4999000	USD
CY2021Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	31000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7821000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-50379000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	370228000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-37630000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-50379000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	687000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	688000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	151000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	-272000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7023000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7821000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1514000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2111000	USD
CY2022Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	4986000	USD
CY2021Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1187000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6940000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2009000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-307000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-308000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-229000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6704000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7103000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-168000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	474000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46746000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53541000	USD
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	163504000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	115168000	USD
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	110566000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	60940000	USD
CY2022Q1	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	0	USD
CY2021Q1	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	11838000	USD
CY2022Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	79000	USD
CY2021Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	136000	USD
CY2022Q1	us-gaap	Payments For Software PaymentsForSoftware	0	USD
CY2021Q1	us-gaap	Payments For Software PaymentsForSoftware	1039000	USD
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2021Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53017000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-67247000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	405000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4999000	USD
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	30000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	405000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5029000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-99358000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-115759000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231900000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	272350000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132542000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	156591000	USD
CY2022Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	13000	USD
CY2021Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	425000	USD
CY2022Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	281000	USD
CY2021Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	63000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5804000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131636000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156591000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	906000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132542000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	156591000	USD
CY2022Q1	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. The Company is also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash, cash equivalents, restricted cash and investments of $418.8 million as of March 31, 2022, the Company believes that it has sufficient resources to fund its operations for at least the next few years beyond the date that the unaudited condensed consolidated financial statements are issued.</span></div>
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	auph	Cash Cash Equivalents And Debt Securities Current CashCashEquivalentsAndDebtSecuritiesCurrent	418800000	USD
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	900000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	300000	USD
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately 54% and 45% respectively of the Company's total revenues for the three months ended March 31, 2022. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.</span>
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	277400000	USD
CY2022Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	20400000	USD
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15400000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2022Q1	us-gaap	Interest Receivable InterestReceivable	500000	USD
CY2022Q1	us-gaap	Debt Securities Current DebtSecuritiesCurrent	286200000	USD
CY2021Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	234200000	USD
CY2022Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	8800000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	215000000	USD
CY2021Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	19200000	USD
CY2022Q1	us-gaap	Debt Securities Current DebtSecuritiesCurrent	286210000	USD
CY2021Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	234178000	USD
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	100000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	766000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	6000	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2217000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2217000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	19713000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12566000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4336000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4543000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	26266000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	19326000	USD
CY2022Q1	auph	Prepaid Assets Current PrepaidAssetsCurrent	6351000	USD
CY2021Q4	auph	Prepaid Assets Current PrepaidAssetsCurrent	5316000	USD
CY2022Q1	us-gaap	Prepaid Insurance PrepaidInsurance	682000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1632000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	3966000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	796000	USD
CY2022Q1	auph	Prepaid Rent And Prepaid Continuing Studies PrepaidRentAndPrepaidContinuingStudies	1200000	USD
CY2021Q4	auph	Prepaid Rent And Prepaid Continuing Studies PrepaidRentAndPrepaidContinuingStudies	4762000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12199000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12506000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19470000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11588000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7882000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19470000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11066000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8404000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5331000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	300000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5254000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	999000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	836000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4332000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4418000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	300000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5232000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5383000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1009000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1059000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7562000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7680000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8571000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8739000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y3M18D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0520
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	863000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1061000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1085000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1110000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1135000	USD
CY2022Q1	auph	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	5638000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10892000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2321000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8571000	USD
CY2021Q1	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	21000000	CHF
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	11800000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	78000000	USD
CY2022Q1	auph	Lessee Operating Lease Lease Not Yet Commenced Payments Prior To Commencement Of Lease LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease	885000	USD
CY2022Q1	auph	Lessee Operating Lease Lease Not Yet Commenced Liability To Be Paid LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid	120000	USD
CY2022Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3267000	USD
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3879000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7289000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3428000	USD
CY2022Q1	auph	Accrued Research Current AccruedResearchCurrent	5409000	USD
CY2021Q4	auph	Accrued Research Current AccruedResearchCurrent	4383000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9609000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18242000	USD
CY2022Q1	auph	Commercial Related Accruals Current CommercialRelatedAccrualsCurrent	6753000	USD
CY2021Q4	auph	Commercial Related Accruals Current CommercialRelatedAccrualsCurrent	5015000	USD
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	32327000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	34947000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	17400000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16000000	USD
CY2022Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	286210000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	USD
CY2022Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	418752000	USD
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	234178000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	466078000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-37630000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-50379000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141675000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141675000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127401000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	127401000	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16601000	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15785000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.70
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.66
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0173
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0028
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2022Q1	auph	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.116
CY2021Q1	auph	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.089
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.02
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.72
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12074000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.84
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2800000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.00
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	54000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.57
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	171000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	16.27
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14649000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.66
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7023000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7821000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	48300000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10000	USD

Files In Submission

Name	View Source	Status
R24.htm	Edgar Link	pending
0001628280-22-013439-index-headers.html	Edgar Link	pending
0001628280-22-013439-index.html	Edgar Link	pending
0001628280-22-013439.txt	Edgar Link	pending
0001628280-22-013439-xbrl.zip	Edgar Link	pending
auph-20220331.htm	Edgar Link	pending
auph-20220331.xsd	Edgar Link	pending
auph-20220331_cal.xml	Edgar Link	unprocessable
auph-20220331_def.xml	Edgar Link	unprocessable
auph-20220331_htm.xml	Edgar Link	completed
auph-20220331_lab.xml	Edgar Link	unprocessable
auph-20220331_pre.xml	Edgar Link	unprocessable
auph-2022q1exx311.htm	Edgar Link	pending
auph-2022q1exx312.htm	Edgar Link	pending
auph-2022q1exx321.htm	Edgar Link	pending
auph-2022q1exx322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

2022 Q1 Form 10-Q Financial Statement

#000162828022013439 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH Aurinia Pharmaceuticals Inc. Stock $auph

2022 Q1 Form 10-Q Financial Statement

#000162828022013439 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph